Peremptory results from Insert 3 examination of ipilimumab in patients with metastatic melanoma
Bristol-Myers Squibb Train (NYSE: BMY) today announced unmistakeable results from a Juncture 3 randomized, hypocritical weak-minded bone up on of ipilimumab which demonstrated that complete survival (OS) was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab. The results were statistically expressive since patients receiving ipilimumab by oneself Dare proportion 0.66,>
“Results from this ipilimumab meditate on are overwhelming and grandstand a expose the developing of harnessing the unsusceptible routine to premium cancers metastatic melanoma”
As in other studies of ipilimumab, the most bourgeois side effects reported in the inspect were immune-related and based on the instrument of proceeding. These immune-related adverse events were from time to time simple and life-threatening, and most regularly stiff the gastrointestinal, shell, liver, or endocrine systems.
The information were published today in the Altered England Scrapbook of Medicament and presented at the 46th Annual Convention of the American Association of Clinical Oncology. Conspectus # 4)
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
